[go: up one dir, main page]

MA38454B1 - Inhibiteurs de protéines kinases - Google Patents

Inhibiteurs de protéines kinases

Info

Publication number
MA38454B1
MA38454B1 MA38454A MA38454A MA38454B1 MA 38454 B1 MA38454 B1 MA 38454B1 MA 38454 A MA38454 A MA 38454A MA 38454 A MA38454 A MA 38454A MA 38454 B1 MA38454 B1 MA 38454B1
Authority
MA
Morocco
Prior art keywords
protein kinase
kinase inhibitors
useful
formula
fgfr
Prior art date
Application number
MA38454A
Other languages
English (en)
Other versions
MA38454A1 (fr
Inventor
Srinivasan Rajagopalan
Prasad Appukuttan
Arumugam Karthikeyan Narasingapuram
Ravi Kotrabasaiah Ujjinamatada
Shyla George
Tero Linnanen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MA38454A1 publication Critical patent/MA38454A1/fr
Publication of MA38454B1 publication Critical patent/MA38454B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (i), dans laquelle r1 à r5, a, b, z, z1 et z2 étant tels que définis dans les revendications, et des sels pharmaceutiquement acceptables de celui-ci. Les composés de formule (i) selon l'invention sont utiles en tant qu'inhibiteurs de fgfr et sont utiles dans le traitement d'une affection où l'inhibition de la fgfr kinase est souhaitée, telle que le cancer.
MA38454A 2013-04-04 2014-04-03 Inhibiteurs de protéines kinases MA38454B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN382KO2013 2013-04-04
PCT/FI2014/000003 WO2014162039A1 (fr) 2013-04-04 2014-04-03 Inhibiteurs de protéines kinases

Publications (2)

Publication Number Publication Date
MA38454A1 MA38454A1 (fr) 2018-02-28
MA38454B1 true MA38454B1 (fr) 2018-11-30

Family

ID=50685938

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38454A MA38454B1 (fr) 2013-04-04 2014-04-03 Inhibiteurs de protéines kinases

Country Status (33)

Country Link
US (1) US20160031855A1 (fr)
EP (1) EP2981533B1 (fr)
JP (1) JP6356782B2 (fr)
KR (1) KR20150138383A (fr)
CN (1) CN105073733B (fr)
AR (1) AR095781A1 (fr)
AU (1) AU2014246961B2 (fr)
BR (1) BR112015025413A2 (fr)
CA (1) CA2907855A1 (fr)
CL (1) CL2015002932A1 (fr)
CY (1) CY1120306T1 (fr)
DK (1) DK2981533T3 (fr)
EA (1) EA031076B1 (fr)
ES (1) ES2658183T3 (fr)
HR (1) HRP20180382T1 (fr)
HU (1) HUE036692T2 (fr)
LT (1) LT2981533T (fr)
MA (1) MA38454B1 (fr)
MX (1) MX2015013776A (fr)
MY (1) MY184528A (fr)
NO (1) NO2981533T3 (fr)
NZ (1) NZ713410A (fr)
PE (1) PE20160115A1 (fr)
PH (1) PH12015502284A1 (fr)
PL (1) PL2981533T3 (fr)
PT (1) PT2981533T (fr)
RS (1) RS56942B1 (fr)
SA (1) SA515361260B1 (fr)
SG (1) SG11201508125XA (fr)
SI (1) SI2981533T1 (fr)
TW (1) TWI628176B (fr)
UA (1) UA115176C2 (fr)
WO (1) WO2014162039A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
JP5925978B1 (ja) 2014-08-18 2016-05-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の塩およびその結晶
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2974937C (fr) 2015-03-25 2023-09-05 National Cancer Center Agent therapeutique contre le cancer du canal choledoque
KR102486722B1 (ko) 2015-12-17 2023-01-11 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료제
US10487863B2 (en) * 2017-02-17 2019-11-26 Ford Global Technologies, Llc Castellated joint for improved adhesive coverage when using mechanical fixings and adhesive in one joint
CA3054976A1 (fr) 2017-03-16 2018-09-20 Jiangsu Hengrui Medicine Co., Ltd. Derive d'heteroaryl[4,3-c]pyrimidine-5-amine, son procede de preparation et ses utilisations medicales
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
EP3985005A4 (fr) 2019-06-14 2023-07-19 CGeneTech (Suzhou, China) Co., Ltd. Composé cyclique fusionné en tant qu'inhibiteur double de fgfr et vegfr
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114072402B (zh) 2019-07-26 2023-12-26 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的吡啶衍生物
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
KR20230134545A (ko) * 2021-01-26 2023-09-21 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 메틸피라졸로로 치환된 피리도 이미다졸계 화합물의결정형 및 이의 제조방법
KR102655210B1 (ko) * 2021-03-26 2024-04-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CA3220155A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques utiles en tant qu'inhibiteurs de fgfr

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000207A1 (fr) * 1999-06-30 2001-01-04 Merck & Co., Inc. Composes inhibiteurs de la src kinase
JP2003503354A (ja) * 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
CA2535896A1 (fr) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs d'un ensemble de benzimidazolyle c n substitue
CA2666116A1 (fr) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides utiles en tant qu'inhibiteurs de proteine kinase
HRP20150642T1 (hr) * 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
JP5442449B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CN102216300B (zh) * 2009-09-30 2014-10-22 贝达药业股份有限公司 作为蛋白激酶抑制剂的化合物和组合物
UA111382C2 (uk) * 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази

Also Published As

Publication number Publication date
CN105073733B (zh) 2017-06-27
UA115176C2 (uk) 2017-09-25
BR112015025413A2 (pt) 2017-07-18
KR20150138383A (ko) 2015-12-09
NZ713410A (en) 2018-07-27
JP2016515604A (ja) 2016-05-30
SG11201508125XA (en) 2015-10-29
EA201591913A1 (ru) 2016-03-31
WO2014162039A1 (fr) 2014-10-09
AR095781A1 (es) 2015-11-11
CN105073733A (zh) 2015-11-18
PT2981533T (pt) 2018-02-27
SI2981533T1 (en) 2018-04-30
US20160031855A1 (en) 2016-02-04
SA515361260B1 (ar) 2017-08-27
EA031076B1 (ru) 2018-11-30
HRP20180382T1 (hr) 2018-04-06
DK2981533T3 (en) 2018-02-12
HUE036692T2 (hu) 2018-07-30
AU2014246961A1 (en) 2015-10-22
CY1120306T1 (el) 2019-07-10
CL2015002932A1 (es) 2016-04-22
JP6356782B2 (ja) 2018-07-11
PE20160115A1 (es) 2016-03-03
HK1217198A1 (zh) 2016-12-30
MA38454A1 (fr) 2018-02-28
MX2015013776A (es) 2016-02-26
TWI628176B (zh) 2018-07-01
PL2981533T3 (pl) 2018-04-30
ES2658183T3 (es) 2018-03-08
PH12015502284B1 (en) 2016-02-01
MY184528A (en) 2021-04-01
RS56942B1 (sr) 2018-05-31
TW201524970A (zh) 2015-07-01
PH12015502284A1 (en) 2016-02-01
EP2981533B1 (fr) 2017-12-06
LT2981533T (lt) 2018-02-26
NO2981533T3 (fr) 2018-05-05
AU2014246961B2 (en) 2017-09-28
CA2907855A1 (fr) 2014-10-09
EP2981533A1 (fr) 2016-02-10

Similar Documents

Publication Publication Date Title
MA38454A1 (fr) Inhibiteurs de protéines kinases
MA54327B1 (fr) Inhibiteurs de kras g12c
MA46337A (fr) Composé de pyridine
MA44820B1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
SA521421205B1 (ar) مشتقات 6-(4-أمينو-3-أوكسا-8-ازاسبيرو[4.5]ديكان-8-يل)-3-(2.3-داي كلورو فينيل)-2-ميثيل بيريميدين-4(3h)-اون والمركبات ذات الصلة مثل مثبطات ptpn11 (shp2) لعلاج السرطان
PH12020551464A1 (en) Cd73 inhibitors
MA52948B1 (fr) Composés
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
UA111382C2 (uk) Інгібітори протеїнкінази
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
MA42341A1 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MA39983B1 (fr) Dérivés de carboxamide
ZA202207449B (en) Selective cdk4/6 inhibitor cancer therapeutics
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
BR112018010812A2 (pt) compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA44383B1 (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
ZA202307021B (en) Selective cdk4/6 inhibitor cancer therapeutics